4,073 Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH) Acquired by Foster & Motley Inc.

Foster & Motley Inc. purchased a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,073 shares of the company’s stock, valued at approximately $249,000.

A number of other institutional investors and hedge funds have also modified their holdings of PBH. Provence Wealth Management Group acquired a new stake in Prestige Consumer Healthcare during the 3rd quarter valued at $26,000. Pacer Advisors Inc. grew its holdings in Prestige Consumer Healthcare by 85.7% during the 4th quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock valued at $27,000 after buying an additional 204 shares during the last quarter. ORG Partners LLC acquired a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $36,000. International Assets Investment Management LLC grew its holdings in Prestige Consumer Healthcare by 1,900.0% during the 4th quarter. International Assets Investment Management LLC now owns 980 shares of the company’s stock valued at $60,000 after buying an additional 931 shares during the last quarter. Finally, Global Retirement Partners LLC grew its holdings in Prestige Consumer Healthcare by 22.6% during the 3rd quarter. Global Retirement Partners LLC now owns 1,364 shares of the company’s stock valued at $78,000 after buying an additional 251 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Trading Down 0.1 %

PBH stock opened at $70.08 on Friday. Prestige Consumer Healthcare Inc. has a 52-week low of $55.96 and a 52-week high of $75.31. The stock’s fifty day simple moving average is $70.90 and its 200-day simple moving average is $64.12. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.92 and a current ratio of 3.09.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 8th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.04 by $0.02. Prestige Consumer Healthcare had a positive return on equity of 14.09% and a negative net margin of 7.11%. The business had revenue of $282.74 million for the quarter, compared to analysts’ expectations of $280.25 million. During the same quarter last year, the firm earned $1.04 earnings per share. The business’s revenue was up 2.6% on a year-over-year basis. Equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.33 EPS for the current year.

Wall Street Analysts Forecast Growth

PBH has been the topic of a number of analyst reports. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, February 10th. TheStreet upgraded Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a report on Monday, February 12th. One equities research analyst has rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.00.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 5,336 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $69.00, for a total value of $368,184.00. Following the transaction, the senior vice president now directly owns 15,934 shares of the company’s stock, valued at approximately $1,099,446. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.